Pre-MENAC Study
Research type
Research Study
Full title
A feasibility study of Multimodal Exercise/Nutrition/Anti-inflammatory treatment for Cachexia – the pre-MENAC study
IRAS ID
79357
Contact name
Barry Laird
Contact email
Eudract number
2010-022897-14
Clinicaltrials.gov Identifier
Research summary
Cachexia is a syndrome characterized by poor appetite, fatigue, severe weight loss and decreased muscle strength. In cancer, cachexia accounts for 20% of cancer related deaths through immobility, heart or lung failure and is most common in patients with pancreatic and lung cancer. Cancer cachexia is responsible for a reduction in quality of life, but also shorter survival time irrespective of cancer type or the extent of disease. There is evidence that anti-inflammatory medication, exercise, nutrition advice and dietary supplements may be beneficial in treating cachexia. These modalities have been effective in isolation however they have not been combined in a multimodal intervention. The pre-MENAC study assesses the feasibility of such a multimodal intervention in cancer cachexia. The results of this study will inform a larger study assessing a multimodal intervention in cancer cachexia. Patients will be randomised to either the treatment arm (multimodal intervention) or will continue with standard care. This will continue for approximately 6 weeks. Following this, patients in the control arm will be offered the intervention. This will be an open study. The main assessments of the study efficacy will be recruitment and compliance with the multimodal intervention.
REC name
West of Scotland REC 1
REC reference
11/WS/0067
Date of REC Opinion
6 Oct 2011
REC opinion
Favourable Opinion